MeiraGTx (MGTX) Proxy Filing summary

Executive summary

• The annual general meeting is scheduled for June 12, 2025, via live webcast, with shareholders able to vote electronically or by proxy.

• Key business includes electing a Class I director, ratifying the appointment of Ernst & Young LLP as auditor, and addressing other business as may arise.

• Shareholders of record as of April 14, 2025, are entitled to vote; quorum requires at least one third of voting share capital present.

• The company achieved significant clinical, regulatory, and financial milestones in 2024, including successful trials, regulatory designations, and major financing events.

Voting matters and shareholder proposals

• Shareholders will vote on the election of Thomas E. Shenk, Ph.D. as Class I director for a term expiring at the 2028 annual meeting.

• Ratification of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2025, is on the agenda.

• Shareholder proposals for the 2026 annual meeting must be submitted by December 31, 2025.

Board of directors and corporate governance

• The board consists of seven directors divided into three classes with staggered three-year terms.

• Five of seven directors are independent under Nasdaq rules; the board regularly reviews governance guidelines.

• Four standing committees: Audit, Compensation, Nominating and Corporate Governance, and Science and Technology.

• The board separates the roles of Chairman and CEO, with Dr. Harris serving as independent Chairman.

• Director nominations consider integrity, experience, diversity, and shareholder interests.